BeOne Medicines (ONC) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $124.8 million.
- BeOne Medicines' Net Income towards Common Stockholders rose 20287.68% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 10796.67%. This contributed to the annual value of -$644.8 million for FY2024, which is 2687.08% up from last year.
- According to the latest figures from Q3 2025, BeOne Medicines' Net Income towards Common Stockholders is $124.8 million, which was up 20287.68% from $94.3 million recorded in Q2 2025.
- In the past 5 years, BeOne Medicines' Net Income towards Common Stockholders ranged from a high of $215.4 million in Q3 2023 and a low of -$590.7 million during Q4 2021
- Over the past 5 years, BeOne Medicines' median Net Income towards Common Stockholders value was -$348.4 million (recorded in 2023), while the average stood at -$250.1 million.
- Per our database at Business Quant, BeOne Medicines' Net Income towards Common Stockholders plummeted by 75448.23% in 2022 and then soared by 20287.68% in 2025.
- Quarter analysis of 5 years shows BeOne Medicines' Net Income towards Common Stockholders stood at -$590.7 million in 2021, then rose by 24.61% to -$445.3 million in 2022, then rose by 17.47% to -$367.6 million in 2023, then soared by 58.68% to -$151.9 million in 2024, then soared by 182.2% to $124.8 million in 2025.
- Its last three reported values are $124.8 million in Q3 2025, $94.3 million for Q2 2025, and $1.3 million during Q1 2025.